Hormone Replacement Therapy: HRT & TRT Guide

One-minute decision guide

The simple evidence-based answer

Start with the clinical problem, not a target “youthful” number. For menopause symptoms, discuss age, time since menopause, uterus status, clot and cancer history, route and dose; estrogen with an intact uterus usually requires endometrial protection. For testosterone, require compatible symptoms plus repeat accurate morning levels and evaluation of the cause. Discuss fertility before TRT because it can suppress sperm production. Use regulated products, the lowest effective dose for the goal, scheduled monitoring and periodic reassessment.^{See reference 1,See reference 2,See reference 3}

One-minute decision guide

The simple evidence-based answer

The 10 rules to remember

Use hormone replacement therapy only for a clearly defined problem^{See reference 1}
Start with the lowest-burden evidence-based option^{See reference 2}
Record a baseline before changing anything^{See reference 3}
Do not confuse a biological mechanism with a proven health outcome^{See reference 4}
Do not let hormone replacement therapy replace established care^{See reference 5}
Use qualified clinical oversight when the intervention is medical^{See reference 6}
Stop when harms, abnormal symptoms or a worse trend appear^{See reference 7}
Judge benefit with measurements that matter to the original goal^{See reference 8}
Reassess cost, burden and uncertainty after the planned trial^{See reference 9}
Avoid protocols based only on testimonials, influencers or clinic marketing^{See reference 10}

First principles: what this can actually change

Hormones are systemic signals with benefits and harms across multiple tissues; replacing a true deficiency differs from pushing levels above physiological need.^{See reference 1,See reference 2}

Age-related population averages do not by themselves define a disease or treatment target.^{See reference 3,See reference 4}

Route, dose, timing, co-therapy and baseline risk can materially change the benefit-risk balance.^{See reference 5,See reference 6}

A practical decision protocol

Stage: 1. Diagnose
What to do: Confirm symptoms, appropriate labs and underlying cause
Why it matters: Numbers without context cause overtreatment^{See reference 1,See reference 2}

Stage: 2. Stratify risk
What to do: Review fertility, cancer, clotting, sleep apnea and cardiovascular history
Why it matters: Contraindications are therapy-specific^{See reference 3,See reference 4}

Stage: 3. Choose product
What to do: Use regulated formulations and the least burdensome effective route
Why it matters: Custom blends add uncertainty^{See reference 5,See reference 6}

Stage: 4. Monitor
What to do: Track symptom response and therapy-specific safety markers
Why it matters: Benefit without safety data is incomplete^{See reference 7,See reference 8}

Stage	What to do	Why it matters
1. Diagnose	Confirm symptoms, appropriate labs and underlying cause	Numbers without context cause overtreatment^{See reference 1,See reference 2}
2. Stratify risk	Review fertility, cancer, clotting, sleep apnea and cardiovascular history	Contraindications are therapy-specific^{See reference 3,See reference 4}
3. Choose product	Use regulated formulations and the least burdensome effective route	Custom blends add uncertainty^{See reference 5,See reference 6}
4. Monitor	Track symptom response and therapy-specific safety markers	Benefit without safety data is incomplete^{See reference 7,See reference 8}

Timing, dose and frequency

Decision: Testosterone testing
Practical answer: Use repeat morning fasting total testosterone and free testosterone when indicated.^{See reference 1,See reference 2}

Decision: Menopause initiation
Practical answer: Benefit-risk is generally more favorable for healthy symptomatic women under 60 or within 10 years of menopause, absent contraindications.^{See reference 3,See reference 4}

Decision: After starting
Practical answer: Review response and adverse effects at the clinician-defined interval, then periodically.^{See reference 5,See reference 6}

Decision: Long term
Practical answer: Continue only while goals and benefit-risk remain favorable; there is no universal stopping age.^{See reference 7,See reference 8}

Decision	Practical answer
Testosterone testing	Use repeat morning fasting total testosterone and free testosterone when indicated.^{See reference 1,See reference 2}
Menopause initiation	Benefit-risk is generally more favorable for healthy symptomatic women under 60 or within 10 years of menopause, absent contraindications.^{See reference 3,See reference 4}
After starting	Review response and adverse effects at the clinician-defined interval, then periodically.^{See reference 5,See reference 6}
Long term	Continue only while goals and benefit-risk remain favorable; there is no universal stopping age.^{See reference 7,See reference 8}

What to measure

Signal: Target symptoms
How: Use a baseline severity and function score
Interpretation: Treatment should improve the reason it was started^{See reference 1,See reference 2}

Signal: Hormone level when relevant
How: Use accurate timed laboratory testing
Interpretation: Avoid dose chasing beyond the therapeutic goal^{See reference 3,See reference 4}

Signal: Blood count and prostate context for TRT
How: Follow guideline-based hematocrit and prostate monitoring
Interpretation: Erythrocytosis and prostate risk need action^{See reference 5,See reference 6}

Signal: Bleeding and breast or endometrial context for MHT
How: Follow symptom and screening guidance
Interpretation: Unexpected bleeding requires evaluation^{See reference 7,See reference 8}

Signal	How	Interpretation
Target symptoms	Use a baseline severity and function score	Treatment should improve the reason it was started^{See reference 1,See reference 2}
Hormone level when relevant	Use accurate timed laboratory testing	Avoid dose chasing beyond the therapeutic goal^{See reference 3,See reference 4}
Blood count and prostate context for TRT	Follow guideline-based hematocrit and prostate monitoring	Erythrocytosis and prostate risk need action^{See reference 5,See reference 6}
Bleeding and breast or endometrial context for MHT	Follow symptom and screening guidance	Unexpected bleeding requires evaluation^{See reference 7,See reference 8}

What the evidence actually shows

The Menopause Society states that hormone therapy is the most effective treatment for vasomotor symptoms and prevents bone loss, with individualized risk by age, timing, route and regimen.^{See reference 1,See reference 2}

The Endocrine Society recommends testosterone only for men with compatible symptoms and unequivocally, consistently low levels after cause evaluation.^{See reference 3,See reference 4}

Neither guideline supports population screening or hormone treatment solely to reverse normal aging.^{See reference 5,See reference 6}

Evidence strength by claim

Claim: Relieves menopause vasomotor symptoms
Confidence: High
Important boundary: Regimen and individual risk matter^{See reference 1,See reference 2}

Claim: Treats pathological male hypogonadism
Confidence: High
Important boundary: Requires symptoms, repeated low levels and cause^{See reference 3,See reference 4}

Claim: Improves fertility in men
Confidence: Low
Important boundary: TRT commonly suppresses spermatogenesis^{See reference 5,See reference 6}

Claim: Prevents aging in healthy adults
Confidence: Very low
Important boundary: No validated anti-aging outcome^{See reference 7,See reference 8}

Claim	Confidence	Important boundary
Relieves menopause vasomotor symptoms	High	Regimen and individual risk matter^{See reference 1,See reference 2}
Treats pathological male hypogonadism	High	Requires symptoms, repeated low levels and cause^{See reference 3,See reference 4}
Improves fertility in men	Low	TRT commonly suppresses spermatogenesis^{See reference 5,See reference 6}
Prevents aging in healthy adults	Very low	No validated anti-aging outcome^{See reference 7,See reference 8}

Limits and common overclaims

HRT can mean menopause therapy, testosterone therapy or unregulated compounded mixtures; these are not interchangeable.^{See reference 4,See reference 7}

Symptoms attributed to hormones may come from sleep apnea, depression, thyroid disease, medicines or other conditions.^{See reference 5,See reference 8}

Observational clinic outcomes are vulnerable to healthy-user and selection bias.^{See reference 6,See reference 9}

A four-step implementation plan

1. Confirm symptoms, appropriate labs and underlying cause^{See reference 1}
2. Review fertility, cancer, clotting, sleep apnea and cardiovascular history^{See reference 2}
3. Use regulated formulations and the least burdensome effective route^{See reference 3}
4. Track symptom response and therapy-specific safety markers^{See reference 4}

Troubleshooting

Problem: No symptom improvement
Likely issue: Diagnosis or dose may be wrong
Better next step: Reassess rather than escalating automatically^{See reference 1,See reference 2}

Problem: High hematocrit on TRT
Likely issue: Excess erythropoietic effect
Better next step: Prompt prescriber review is required^{See reference 3,See reference 4}

Problem: Unexpected vaginal bleeding
Likely issue: Endometrial evaluation may be needed
Better next step: Contact the clinician promptly^{See reference 5,See reference 6}

Problem: Fertility plans change
Likely issue: TRT can suppress sperm
Better next step: See a reproductive specialist before continuing^{See reference 7,See reference 8}

Problem	Likely issue	Better next step
No symptom improvement	Diagnosis or dose may be wrong	Reassess rather than escalating automatically^{See reference 1,See reference 2}
High hematocrit on TRT	Excess erythropoietic effect	Prompt prescriber review is required^{See reference 3,See reference 4}
Unexpected vaginal bleeding	Endometrial evaluation may be needed	Contact the clinician promptly^{See reference 5,See reference 6}
Fertility plans change	TRT can suppress sperm	See a reproductive specialist before continuing^{See reference 7,See reference 8}

Safety and when to get medical help

Risks vary by therapy and include clotting, stroke, breast or endometrial effects, erythrocytosis, acne, edema, infertility, sleep-apnea worsening and drug-specific adverse effects. Do not use hormones from unverified online sources. Chest pain, one-sided leg swelling, stroke symptoms, severe headache, unexpected heavy bleeding or severe breathlessness needs urgent care.^{See reference 1,See reference 5,See reference 9}

Who is most likely to benefit

Appropriately selected symptomatic menopausal women after individualized risk assessment.^{See reference 2,See reference 6}

Men with pathological hypogonadism confirmed by symptoms, repeated accurate levels and cause evaluation.^{See reference 3,See reference 7}

People seeking generic optimization without a diagnosis are more likely to face uncertain benefit and avoidable harm.^{See reference 4,See reference 8}

Track five things

Target symptoms^{See reference 1}
Hormone level when relevant^{See reference 3}
Blood count and prostate context for TRT^{See reference 5}
Bleeding and breast or endometrial context for MHT^{See reference 7}
Decision made after reviewing the result^{See reference 9}

Frequently asked questions

Are bioidentical hormones safer?

A chemically identical regulated hormone can be appropriate, but custom-compounded products are not automatically safer or more effective.^{See reference 1}

Does TRT reduce fertility?

Yes. Exogenous testosterone can markedly suppress sperm production.^{See reference 2}

Does menopause HRT cause cancer?

Risk depends on hormone, regimen, route, duration and individual history; discuss the personalized absolute risk.^{See reference 3}

Should levels be pushed to a young-adult maximum?

No guideline supports supraphysiological anti-aging targets.^{See reference 4}

Does this extend lifespan?

No human trial has shown that hormone replacement therapy extends lifespan. Any longevity claim must be separated from evidence for a specific symptom, diagnosis or surrogate marker.^{See reference 5}

How quickly should it work?

Use repeat morning fasting total testosterone and free testosterone when indicated.^{See reference 6}

Can it replace standard treatment?

No. A complementary tool should not displace care already shown to reduce symptoms, complications or mortality.^{See reference 7}

How do I know whether it helped?

Use a pre-defined outcome such as target symptoms and compare it with a baseline over an appropriate time window.^{See reference 8}

Connect this decision to your wider health picture

LongevityMate helps organize measurements, symptoms, habits and trends so one test, device or treatment stays in context instead of becoming the whole plan.

See how LongevityMate works

References

1. Testosterone Therapy for Hypogonadism
Endocrine Society2018-03-19Guideline
2. Statement on Testosterone Replacement Therapy
Endocrine Society2026-07-16Official guidance
3. Hormone Therapy Position Statement
The Menopause Society2022-07-07Guideline
4. 2025 High Blood Pressure Guideline
American Heart Association2025-08-14Guideline
5. 2026 Guideline on the Management of Dyslipidemia
American Heart Association2026-03-13Guideline
6. Targeting Ageing With Rapamycin and Rapalogs
The Lancet Healthy Longevity2024-02-01Systematic review
7. Sterile Compounding and Injectable NAD
U.S. Food and Drug Administration2024-10-29Official guidance
8. Understanding Unapproved Use of Approved Drugs
U.S. Food and Drug Administration2025-01-01Official guidance
9. Warning About Unapproved Human Cell and Tissue Products
U.S. Food and Drug Administration2026-05-01Official guidance
10. Bulk Drug Substances With Significant Safety Risks
U.S. Food and Drug Administration2026-05-01Official guidance

Editorial transparency

Published by: LongevityMate Editorial Team
Published: 2026-08-21
Updated: 2026-08-21

Medical disclaimer

This guide provides general health education. It does not diagnose a condition, prescribe treatment, replace individualized medical care, or guarantee a health or longevity outcome.

Evidence and editorial policy Methodology AI limitations

Hormone replacement therapy: menopause HRT and testosterone explained

The simple evidence-based answer

The simple evidence-based answer

The 10 rules to remember

First principles: what this can actually change

A practical decision protocol

Timing, dose and frequency

What to measure

What the evidence actually shows

Evidence strength by claim

Limits and common overclaims

A four-step implementation plan

Troubleshooting

Safety and when to get medical help

Who is most likely to benefit

Track five things

Frequently asked questions

Connect this decision to your wider health picture

Related guides

Total testosterone blood test guide

Metformin longevity guide

GLP-1 therapy guide

DEXA guide

Testosterone optimization: testing, causes and safe treatment

Free Testosterone Test: Ranges, Low and High Results, Methods and What It Means

SHBG Blood Test: Ranges, High and Low Results, Testosterone and What It Means

Lipid-lowering therapy: statins, ezetimibe and PCSK9 explained

References

Editorial transparency

Medical disclaimer